Pharming Group N.V. confirms it will report its preliminary (unaudited) fourth quarter and full year 2023 financial results, for the period ended December 31, on Thursday, March 14, 2024.

Expect 10% growth in RUCONEST® revenue, significantly exceeding prior guidance Expect Joenja® revenues of approximately US$18 million with 81 patients on paid therapy at year end

Pharming Group N.V. presents its preliminary, unaudited financial report for the three months ended September 30, 2023.

Pharming Group N.V. confirms it will report its preliminary (unaudited) third quarter 2023 financial results, for the period ended September 30, on Thursday, October 26, 2023.

Pharming Group N.V. announces it will hold an Extraordinary General Meeting of Shareholders (EGM) on Monday, September 25, 2023 at 14:00 CEST.

Pharming Group N.V. presents its preliminary (unaudited) financial report for the second quarter and first half ended June 30, 2023.

Pharming Group N.V. confirms it will report its preliminary (unaudited) second quarter and first half 2023 financial results, for the period ended June 30, on Thursday, August 3, 2023.

Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has entered into a definitive agreement with Novartis Pharma A.G. (“Novartis") to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to Novartis for a pre-agreed, one-time payment of approximately US$21.1 million shortly after closing.

Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM/Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today, the proposal for a specific authorization for the issuance of shares (or rights to acquire shares) to finance mergers, acquisitions, or strategic alliances, was not put up for a vote. All other proposals were approved.

Pharming Group N.V. presents its preliminary, unaudited financial report for the first quarter ended March 31, 2023.